Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [(18)F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)–PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controve...

詳細記述

保存先:
書誌詳細
主要な著者: Corroyer-Dulmont, Aurélien, Pérès, Elodie A., Petit, Edwige, Guillamo, Jean-Sébastien, Varoqueaux, Nathalie, Roussel, Simon, Toutain, Jérôme, Divoux, Didier, MacKenzie, Eric T., Delamare, Jérôme, Ibazizène, Méziane, Lecocq, Myriam, Jacobs, Andréas H., Barré, Louisa, Bernaudin, Myriam, Valable, Samuel
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2013
主題:
Basic and Translational Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3534417/
https://ncbi.nlm.nih.gov/pubmed/23115160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos260
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料